Company intelligence / Profile preview

Bolt Clinical Research and Consulting

Redwood City, California, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~40
Development stage: Other

Overview

Bolt has refocused its pipeline on two key programs after discontinuing development of trastuzumab imbotolimod (BDC‑1001). BDC‑3042, an agonist antibody targeting Dectin‑2, is in Phase 1 dose escalation for multiple solid tumors and has shown promising safety/efficacy signals. BDC‑4182, a next-generation ISAC targeting Claudin 18.2, has demonstrated potent anti-tumor activity preclinically. No approved products yet.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyImmune Stimulating Antibody Conjugate (ISAC)
Industry: Biotech

Partnerships

Genmab (collaboration on immunotherapies)Toray Industries, Inc. (“global cancer immunotherapy co-development”)Innovent Bio (“oncology research and development collaboration” using Boltbody ISAC technology)

Beyond the preview

Go deeper on Bolt Clinical Research and Consulting.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bolt Clinical Research and Consulting.

Explore the full profile